An appeals court has again shot down a US Federal Trade Commission (FTC) lawsuit attempting to brand pay-for-delay pharmaceutical settlement deals anti-competitive – casting more doubt on the chances of its long-running bid to end the deals succeeding in the courtroom.
Several pharmaceutical companies have told a US appeals court that the Federal Trade Commission’s (FTC) attempt to overturn a failed pay-for-delay prosecution should be thrown out.